Premium
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort
Author(s) -
Kim Min,
Snowden Stuart,
Suvitaival Tommi,
Ali Ashfaq,
Merkler David J.,
Ahmad Tahmina,
Westwood Sarah,
Baird Alison,
Proitsi Petroula,
NevadoHolgado Alejo,
Hye Abdul,
Bos Isabelle,
Vos Stephanie,
Vandenberghe Rik,
Teunissen Charlotte,
Kate Mara,
Scheltens Philip,
Gabel Silvy,
Meersmans Karen,
Blin Olivier,
Richardson Jill,
De Roeck Ellen,
Sleegers Kristel,
Bordet Régis,
Rami Lorena,
Kettunen Petronella,
Tsolaki Magda,
Verhey Frans,
Sala Isabel,
Lléo Alberto,
Peyratout Gwendoline,
Tainta Mikel,
Johannsen Peter,
FreundLevi Yvonne,
Frölich Lutz,
Dobricic Valerija,
Engelborghs Sebastiaan,
Frisoni Giovanni B.,
Molinuevo José L.,
Wallin Anders,
Popp Julius,
MartinezLage Pablo,
Bertram Lars,
Barkhof Frederik,
Ashton Nicholas,
Blennow Kaj,
Zetterberg Henrik,
Streffer Johannes,
Visser Pieter J.,
Lovestone Simon,
LegidoQuigley Cristina
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.03.004
Subject(s) - biomarker , dementia , cerebrospinal fluid , alzheimer's disease , medicine , disease , hippocampal formation , cohort , pathology , magnetic resonance imaging , oncology , amyloid (mycology) , cognitive decline , psychology , chemistry , biochemistry , radiology
A critical and as‐yet unmet need in Alzheimer's disease (AD) is the discovery of peripheral small molecule biomarkers. Given that brain pathology precedes clinical symptom onset, we set out to test whether metabolites in blood associated with pathology as indexed by cerebrospinal fluid (CSF) AD biomarkers. Methods This study analyzed 593 plasma samples selected from the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery study, of individuals who were cognitively healthy (n = 242), had mild cognitive impairment (n = 236), or had AD‐type dementia (n = 115). Logistic regressions were carried out between plasma metabolites (n = 883) and CSF markers, magnetic resonance imaging, cognition, and clinical diagnosis. Results Eight metabolites were associated with amyloid β and one with t‐tau in CSF, these were primary fatty acid amides (PFAMs), lipokines, and amino acids. From these, PFAMs, glutamate, and aspartate also associated with hippocampal volume and memory. Discussion PFAMs have been found increased and associated with amyloid β burden in CSF and clinical measures.